September 30, 2024
RadioNano Therapeutics Inc.
Presentative: Masatoshi Chiba, CEO

RadioNano Therapeutics Inc. Raises 450 million Yen in Funding
- Accelerating R&D for novel boron-containing nanoparticle for cancer treatment by Boron Neutron Capture Therapy -

RadioNano Therapeutics Inc. has announced that it has raised around 450 million yen by Innovation Kyoto 2021 Investment Limited Partnership operated by Kyoto University Innovation Capital Co., Ltd. , Mitsubishi UFJ Life Science No. 4 Investment Limited Partnership operated by Mitsubishi UFJ Capital Co. Ltd., DBJ Capital Investment Limited Partnership operated by DBJ Capital Co. Ltd., and Japan Science and Technology Agency.

RadioNano Therapeutics, a venture company, was established with the support of Kyoto University Innovation Capital Co. Ltd. for the social implementation of Boron Neutron Capture Therapy (BNCT) using highly hydrophilic boron-containing inorganic nanoparticles developed by Professor Naoki Komatsu of the Graduate School of Human and Environmental Studies, Kyoto University and Professor Minoru Suzuki of the Institute for Composite Nuclear Science, Kyoto University.

The funds raised will be used to accelerate the development of RN-501, the lead pipeline, for clinical trials and to expand the pipeline.

About RadioNano Therapeutics Inc.:

Establishment:	April 1, 2024
Business:	R&D of highly hydrophilic inorganic nanoparticle products
Headquarters:	36-1 Yoshidahonmachi, Sakyo-ku, Kyoto, JAPAN 606-8501
CEO:	Masatoshi Chiba

About RN-501

RN-501 is a highly hydrophilic boron-containing inorganic nanoparticles that is being developed as a cancer treatment for BNCT. It is characterized by the presence of approximately 5 million ^{10}B (a stable isotope of boron) in one particle, and its excellent accumulation and retention in cancer have demonstrated its strong anticancer effects and high safety in pharmacological models. In addition, it is expected to induce cancer immunity.

About Boron Neutron Capture Therapy (BNCT)

BNCT is a radiation therapy to kill cancer cells by alpha particles and lithium nuclei that uses a nuclear reaction between thermal neutrons and ^{10}B. Neutron beams are harmless to living organisms, and the heavy particles generated by the nuclear reaction are both short in range and their effects are localized, making them a highly selective cancer treatment with little damage to normal tissue. This is called “cancer cell selective therapy”.

Contact:

RadioNano Therapeutics Inc.
36-1 Yoshidahonmachi, Sakyo-ku, Kyoto, JAPAN 606-8501
Administration Dpt. Hiroshi Kawai
contact@radionano-tx.com